Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AFT Pharmaceuticals Ltd. ( (NZ:AFT) ) has provided an announcement.
AFT Pharmaceuticals, New Zealand’s largest domestic pharmaceuticals company, has appointed Stuart Houliston as its new Chief Financial Officer, effective 15 June 2026. He replaces long-serving CFO Malcolm Tubby, who will retire on 29 May, with executive Simon Bosley covering the role in the interim.
Houliston joins from Sanford, the country’s largest integrated fishing and aquaculture group, and brings experience in public markets and audit from his previous role as an audit director at KPMG. AFT’s board and management highlighted his financial expertise as critical to supporting the company’s global growth strategy, underscoring the importance of the CFO transition for sustaining momentum in its expanding international pharmaceuticals business.
More about AFT Pharmaceuticals Ltd.
AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets and distributes a broad portfolio of proprietary and in-licensed medicines across multiple therapeutic categories. Its products, spanning patented, branded and generic drugs, are sold through over-the-counter, prescription and hospital channels in Australia, New Zealand, parts of Asia, North America and Europe, with additional out-licensing to partners in more than 125 countries.
YTD Price Performance: 3.25%
Average Trading Volume: 11,955
Technical Sentiment Signal: Buy
Current Market Cap: N$366M
See more insights into AFT stock on TipRanks’ Stock Analysis page.